临床药师参与镇痛药物治疗对晚期肿瘤患者疼痛疗效的影响 |
| |
引用本文: | 雷旭东,王玉洁,金育忠,柴艳冬,姜晓燕,冯晶,许颖,范春玲.临床药师参与镇痛药物治疗对晚期肿瘤患者疼痛疗效的影响[J].甘肃医药,2014,0(7):503-507. |
| |
作者姓名: | 雷旭东 王玉洁 金育忠 柴艳冬 姜晓燕 冯晶 许颖 范春玲 |
| |
作者单位: | 雷旭东 (甘肃省肿瘤医院药学部, 甘肃 兰州,730050); 王玉洁 (甘肃省肿瘤医院药学部, 甘肃 兰州,730050); 金育忠 (甘肃省肿瘤医院药学部, 甘肃 兰州,730050); 柴艳冬 (甘肃省肿瘤医院药学部, 甘肃 兰州,730050); 姜晓燕 (甘肃省肿瘤医院乳腺科, 甘肃 兰州,730050); 冯晶 (甘肃省肿瘤医院药学部, 甘肃 兰州,730050); 许颖 (甘肃省肿瘤医院药学部, 甘肃 兰州,730050); 范春玲 (甘肃省肿瘤医院药学部, 甘肃 兰州,730050); |
| |
摘 要: | 目的:探讨临床药师参与镇痛药物治疗工作后,对晚期肿瘤患者疼痛治疗效果的影响。方法:收集重度癌痛患者30例,比较临床药师参与止痛治疗3周前后的治疗效果、不良反应及治疗成本间的差异,并进行成本效益分析。结果:药师参与癌痛治疗前后最严重最痛时评分分别为8.27、6.47,差异比较有统计学意义(P〈0.05);爆发痛次数分别为4.63、2.96,差异比较有统计学意义(P〈0.05)、服药后止痛药物持续起效时间(NRS≤4)分别为4.58、8.46,差异比较有统计学意义(P〈0.05);总缓解率分别为:46.67%、86.67%,差异比较有统计学意义(P〈0.05);在不良反应方面比较没有差异;治疗成本方面药师参与后费用较参与前高,但成本效益分析发现,药师参与后患者获益率较高。结论:临床药师在参与晚期肿瘤患者的疼痛治疗后,在不良反应没有增加的情况下,患者的止痛效果明显提高,临床获益率提高。
|
关 键 词: | 临床药师 癌痛 疗效 不良反应 成本效益 |
Clinical pharmacists involved in analgesic treatment on the efficacy of pain in patients with advanced cancer |
| |
Institution: | LEI Xu-dong, WANG Yu-jie, JIN Yu-zhong, CAAI Yan-dong, JIANG Xiao-yan, FENG Jing, XU Ying, FAN Chun-ling (1 Department of Pharmacy ; 2.Department of Breast surgerg; Tumor Hospital of Gansu Province, Lanzhou 730050, China) |
| |
Abstract: | To investigate the clinical pharmacists involved in analgesic medications work , treatment of pain in patients with advanced cancer effects . Methods: 30 patients with severe cancer pain , more clinical pharmacists involved in pain treatment difference after three weeks of treatment effects , adverse reactions and treatment costs between cost and benefit analysis . Results:The participation of pharmacists before and after treatment of the most severe pain most pain scores were 8 . 27 , 6 . 47 , the difference was statistically significant(P〈0 . 05); breakthrough pain were 4 . 63 , 2 . 96 times , the difference was statistically significant(P〈0 . 05), after taking pain medications continue onset time(NRS≤4) were 4 . 58 , 8 . 46 , the difference was statistically significant (P〈0 . 05);overall response rates were: 46 . 67%, 86 . 67%, comparing statistical difference significance (P〈0 . 05);relatively no difference in adverse reactions ; front costs involved in treatment costs compared with pharmacists participating in high , but the cost-benefit analysis found that the pharmacists involved in a high rate of patient benefit . Conclusion: The clinical pharmacists to participate in the treatment of pain in patients with advanced cancer , no increase in adverse circumstances , the analgesic effect in patients with significantly improved clinical benefit rate . |
| |
Keywords: | clinic pharmacist cancer pain efficacy adverse efficacy cost-effectiveness |
本文献已被 维普 等数据库收录! |
|